All Respiratory articles
-
InformationGINA ASTHMA STRATEGY 2020
Asthma affects an estimated 300 million individuals worldwide, and still imposes an unacceptable burden on healthcare systems, society through loss of productivity in the workplace, and, especially for paediatric asthma, disruption to the family. Asthma affects all age groups and contributes to many deaths worldwide. The Global Initiative for ...
-
Working party guideline/algorithm
Inhaler choice guideline
Information is intended for healthcare professionals only. This management algorithm was developed by MGP Ltd and supported by Chiesi Ltd through the provision of a grant for its production. Chiesi Ltd had no editorial control other than to check factual accuracy. See end of algorithm for ...
-
On demand webinars
A practical approach to COPD treatment: case studies to support patient care*
This webinar has been organised and funded by GSK UK. See bottom of page for full disclaimer. *This GSK webinar contains promotional content Video: A practical approach to COPD treatment: case studies to support patient care Incruse▼ Ellipta (umeclidinium bromide): prescribing information ...
-
Independent professional body guideline
GINA strategy 2020: assessing patients with asthma
This Guidelines summary outlines recommendations for assessing patients with asthma. Please refer to the full report for the complete set of recommendations.
-
Independent professional body guideline
GINA strategy 2020: asthma–COPD overlap
This Guidelines summary outlines recommendations for the diagnosis and initial treatment of adults with features of asthma, chronic obstructive pulmonary disease (COPD), or both.
-
Independent professional body guideline
GINA strategy 2020: management of asthma
This Guidelines summary outlines recommendations for the management of asthma in adults, adolescents, and children aged six to 11.
-
Independent professional body guideline
GINA strategy 2020: diagnosis of asthma
This Guidelines summary outlines recommendations for making the diagnosis of asthma in adults and children over five years of age. Please refer to the full report for the complete set of recommendations.
-
On demand webinars
A practical approach to COPD treatment: case studies to support patient care*
This webinar has been organised and funded by GSK UK. See bottom of page for full disclaimer. *This GSK webinar contains promotional content Video: A practical approach to COPD treatment: case studies to support patient care Incruse▼Ellipta (umeclidinium bromide): prescribing information Anoro▼Ellipta ...
-
Prescribing summary card
DuoResp® Spiromax® (budesonide/formoterol)
Information intended for healthcare professionals only. This prescribing summary card was developed from content provided by Teva UK Limited in a format developed by Guidelines . Teva UK Limited commissioned the development of the prescribing card and carried out full medical approval to ensure compliance with regulations. ...
-
Video
Dr Kevin Gruffydd–Jones Q&A on asthma
In this video, taken at Guidelines Live 2019, Dr Kevin Gruffydd–Jones answers questions on recent asthma guidelines updates, significant differences between the guideline updates, what is on the horizon for asthma guidelines, and his key take-home messages.
-
NICE guideline
COVID-19 rapid guideline: pneumonia in adults
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic.
-
NICE guideline
COVID-19 rapid guideline: cystic fibrosis
The purpose of this Guidelines summary is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic. ...
-
NICE guideline
COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)
The purpose of this summary is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources. For more detailed information, please refer to the full guideline ...
-
NICE guideline
COVID-19 rapid guideline: severe asthma
The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.
-
Information
ClinOwl: a new resource for healthcare professionals
ClinOwl is a new content discovery platform for healthcare professionals, delivering the latest clinical articles from the leading medical journals in a single view Browse and search over 18,000 articles organised across 40+ clinical specialties and sub-specialties. You can also sign up to ...
-
Independent professional body guideline
Managing malnutrition in COPD
Advice on the risk of malnutrition in patients with COPD and managing nutrition appropriately; includes a pathway on oral nutritional supplements.
-
NICE guideline
NICE asthma guideline: diagnosis and monitoring
A concise summary on the initial assessment, diagnosis, and monitoring of asthma in adults, young people, and children. Includes assessment algorithms.
-
NICE guideline
NICE asthma guideline: chronic asthma management
A practical summary of NICE recommendations on managing chronic asthma in children, young people, and adults, including three management algorithms.
-
Supplement
The re-usable Respimat® Soft Mist™ inhaler
Information for healthcare professionals only. This supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines for Nurses . Please see bottom of page for full disclaimer. View prescribing information Download the supplement Foreword Jane Scullion, ...
-
Supplement
The re-usable Respimat® Soft Mist™ inhaler
Information for healthcare professionals only. This supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines . Please see bottom of page for full disclaimer. View prescribing information Download the supplement The re-usable Respimat ® Soft ...
